MX2019002879A - Compuestos novedosos y usos terapeuticos de los mismos. - Google Patents

Compuestos novedosos y usos terapeuticos de los mismos.

Info

Publication number
MX2019002879A
MX2019002879A MX2019002879A MX2019002879A MX2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A MX 2019002879 A MX2019002879 A MX 2019002879A
Authority
MX
Mexico
Prior art keywords
novel compounds
therapeutic uses
compounds
novel
pathogen
Prior art date
Application number
MX2019002879A
Other languages
English (en)
Inventor
Westby Michael
Glossop Melanie
Watson Christine
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615560.8A external-priority patent/GB201615560D0/en
Priority claimed from GBGB1707076.4A external-priority patent/GB201707076D0/en
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Publication of MX2019002879A publication Critical patent/MX2019002879A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion esta relacionada con compuestos novedosos con la habilidad para vincular una respuesta inmune a un patogeno, al uso de dichos compuestos en una enfermedad o trastorno mediado y/o causado por un agente infeccioso, a composiciones que contienen dichos compuestos, procesos para su preparacion y a intermediarios novedosos utilizados en dichos procesos.
MX2019002879A 2016-09-13 2017-09-13 Compuestos novedosos y usos terapeuticos de los mismos. MX2019002879A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1615560.8A GB201615560D0 (en) 2016-09-13 2016-09-13 Novel compounds and therapeutic uses thereof
GBGB1707076.4A GB201707076D0 (en) 2017-05-04 2017-05-04 Novel compounds and therapeutic uses thereof
PCT/GB2017/052699 WO2018051085A1 (en) 2016-09-13 2017-09-13 Novel compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2019002879A true MX2019002879A (es) 2019-09-18

Family

ID=59923474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002879A MX2019002879A (es) 2016-09-13 2017-09-13 Compuestos novedosos y usos terapeuticos de los mismos.

Country Status (14)

Country Link
US (1) US11014966B2 (es)
EP (1) EP3512544B1 (es)
JP (2) JP7185622B2 (es)
KR (1) KR102544465B1 (es)
CN (1) CN110022896B (es)
AU (1) AU2017328896A1 (es)
BR (1) BR112019004877A2 (es)
CA (1) CA3036405A1 (es)
DK (1) DK3512544T3 (es)
ES (1) ES2854991T3 (es)
IL (1) IL265269B (es)
MX (1) MX2019002879A (es)
WO (1) WO2018051085A1 (es)
ZA (1) ZA201901422B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201804098D0 (en) * 2018-03-14 2018-04-25 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201904534D0 (en) 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
KR20050099536A (ko) * 2003-02-06 2005-10-13 트리펩 아베 글리코실화된 특이성 교환체
ES2395126T3 (es) * 2003-02-28 2013-02-08 Agenus Inc. Uso de lectinas para promover la oligomerización de glicoproteínas y de moléculas antigénicas
CA2760774A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
TWI608019B (zh) * 2011-11-18 2017-12-11 新製藥授權控股有限公司 多黏菌素衍生物
JPWO2016104647A1 (ja) 2014-12-25 2017-10-05 国立大学法人大阪大学 糖鎖結合ワクチン抗原及び糖鎖導入剤
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
EP3512544B1 (en) 2020-10-28
KR20190064592A (ko) 2019-06-10
DK3512544T3 (da) 2021-02-01
ES2854991T3 (es) 2021-09-23
EP3512544A1 (en) 2019-07-24
US20190248838A1 (en) 2019-08-15
CN110022896A (zh) 2019-07-16
WO2018051085A1 (en) 2018-03-22
BR112019004877A2 (pt) 2019-06-11
CA3036405A1 (en) 2018-03-22
KR102544465B1 (ko) 2023-06-19
JP2019526614A (ja) 2019-09-19
US11014966B2 (en) 2021-05-25
ZA201901422B (en) 2020-11-25
IL265269B (en) 2022-04-01
IL265269A (en) 2019-05-30
CN110022896B (zh) 2023-12-19
JP7185622B2 (ja) 2022-12-07
AU2017328896A1 (en) 2019-04-04
JP2022184922A (ja) 2022-12-13

Similar Documents

Publication Publication Date Title
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
PH12017501216A1 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
WO2016127179A3 (en) Immunomodulatory agents
PH12017501522B1 (en) Antibodies to tau and uses thereof
MX2017003211A (es) Anticuerpos anti-met y composiciones.
PH12016501968A1 (en) Novel macrocyclic compounds
PH12018500379A1 (en) Biopharmaceutical compositions
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2019002879A (es) Compuestos novedosos y usos terapeuticos de los mismos.
IN2014CH00840A (es)
MX2017015279A (es) Exasomas y su uso como vacunas.
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
PH12018500201A1 (en) Enhanced immune response in porcine species
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
ZA201906580B (en) Novel compounds and therapeutic uses thereof
EA201990710A1 (ru) Новые соединения и их терапевтические применения
WO2015186139A3 (en) Novel polymorphs of tenofovir disoproxil oxalate and process for preparation of the same
LV14852A (lv) Triazolilpurīna atvasinājumi kā pretvīrusu preparāti